Bendamustine associated immune suppression and infections during therapy of hematological malignancies
- 5 October 2015
- journal article
- review article
- Published by Informa UK Limited in Leukemia & Lymphoma
- Vol. 57 (3), 512-519
- https://doi.org/10.3109/10428194.2015.1110748
Abstract
Bendamustine is being increasingly used in patients with indolent non-Hodgkin lymphoma, mantle cell lymphoma and chronic lymphocytic leukemia. This review summarizes available evidence regarding the effects of bendamustine on the immune system, examines its role in consequent infections as reported in randomized controlled trials, prospective observational investigations, retrospective studies and individual published case reports. Myelosuppression including lymphopenia occurs relatively frequently after therapy with bendamustine. It is mostly CD4 + T cell counts that are suppressed, yet when given in combination with rituximab, both T cell and B cell depletion have been recorded. In addition, hypogammaglobulinemia after bendamustine therapy has also been reported. Variable infection rates have been documented and these include different bacterial, viral and fungal infections. Finally, we also consider issues relating to the use of prophylactic antibiotics in patients receiving the drug.Keywords
This publication has 47 references indexed in Scilit:
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialThe Lancet, 2013
- Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemiaAnnals of Hematology, 2013
- Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignanciesExpert Opinion on Drug Metabolism & Toxicology, 2012
- Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study GroupJournal of Clinical Oncology, 2011
- Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins LymphomaClinical Medicine Insights: Oncology, 2011
- Optimal Use of Bendamustine in Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphomas, and Multiple Myeloma: Treatment Recommendations From an International Consensus PanelClinical Lymphoma Myeloma and Leukemia, 2010
- Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2009
- Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent StudyJournal of Clinical Oncology, 2008
- Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating AgentsClinical Cancer Research, 2008
- Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)Zeitschrift für Krebsforschung und Klinische Onkologie, 2005